Success Stories

Event Videos

Type 1 primary hyperoxaluria: From childhood to adult, how to manage adequately medical therapy compliance? https://www.ncbi.nlm.nih.gov/pubmed/29198962 Nephrol Ther. 2017 Nov 29. pii: S1769-7255(17)30583-7. doi: 10.1016/j.nephro.2017.06.004. [Epub ahead of print] Leflot M, Krzesinski JM, Collard L, Thomas A, Ghuysen MS. Abstract Published on: Nov-2017 Read more	Quality of life of biliary atresia after living donor liver transplant in Japan https://www.ncbi.nlm.nih.gov/pubmed/29067750 Pediatr Int. 2017 Oct 25. doi: 10.1111/ped.13442. [Epub ahead of print] Kikuchi R, Mizuta K, Urahashi T, Sanada Y, Yamada N, Onuma E, Sato I1, Kamibeppu K. Abstract BACKGROUND: Health-related quality of life (HRQOL) is an important outcome in solid organ transplantation. This study evaluated and explored the factors of generic and transplant-specific HRQOL in Japanese pediatric and adolescent patients with biliary atresia (BA) after living donor liver transplant (LDLT). METHODS: Published on: Oct-2017 Read more
Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia. https://www.ncbi.nlm.nih.gov/pubmed/29201126 Iran J Child Neurol. 2017 Fall;11(4):66-70. Honar N, Shakibazad N, Serati Shirazi Z, Dehghani SM, Inaloo S. Abstract OBJECTIVE: Tyrosinemia type 1 is a hereditary disorder with liver, kidney and nervous system involvement. Neurological crises can occur in tyrosinemic patients without treatment or when treatment stops. Here we report three children that developed diaphragmatic paralysis after discontinuation of nitisinone. In patients with tyrosinemia type 1, combined treatment with nitisinone and a low-tyrosine diet have prevented neurological crises. The purpose of this article was to express the importance of taking nitisinone (NTBC) for tyrosinemia diseases and risks of inadvertent discontinuation. MATERIALS & METHODS: Published on: Nov-2017 Read more	A comparison of lipid minimization strategies in children with intestinal failure https://www.ncbi.nlm.nih.gov/pubmed/29079315 \ Nutrition associated liver disease J Pediatr Surg. 2017 Oct 12. pii: S0022-3468(17)30652-8. doi: 10.1016/j.jpedsurg.2017.10.030. [Epub ahead of print] Gonzalez-Hernandez J, Prajapati P, Ogola G, Nguyen V, Channabasappa N, Piper HG. Abstract PURPOSE: The purpose of this study was to compare outcomes of lipid minimization with either Intralipid (IL) or Omegaven® in children with intestinal failure (IF) who developed intestinal failure-associated liver disease (IFALD) while receiving parenteral nutrition (PN). METHODS: Published on: Oct-2017 Read more
Effects of activated carbon N-acetylcysteine sustained-release microcapsule on dipeptidyl peptidase IV expression in young rats with non-alcoholic fatty liver disease https://www.ncbi.nlm.nih.gov/pubmed/29201174 NAFLD Exp Ther Med. 2017 Nov;14(5):4737-4744. doi: 10.3892/etm.2017.5128. Epub 2017 Sep 19. Zhou H, Shi T, Yan J, Chen X, Liao L, Zhao S, Fang H, Zhuang R. Abstract Published on: Nov-2017 Read more	Next generation sequencing in pediatric hepatology and liver transplantation https://www.ncbi.nlm.nih.gov/pubmed/29080241 Liver Transpl. 2017 Oct 28. doi: 10.1002/lt.24964. [Epub ahead of print] Nicastro E, D'Antiga L. Abstract Published on: Oct-2017 Read more
A favorable response to the immunosuppressive combination therapy with mizoribine and azathioprine in children with primary sclerosing cholangitis https://www.ncbi.nlm.nih.gov/pubmed/29059700 Hepatol Res. 2017 Oct 23. doi: 10.1111/hepr.12993. [Epub ahead of print] . Tajiri H, Zen Y, Takano T, Brooks S. Abstract AIM: Primary sclerosing cholangitis (PSC), with no curative intervention, can progress to end-stage liver disease. Mizoribine, a purine anti-metabolic, has never been used for the management of PSC. To evaluate the role of mizoribine with azathioprine we performed a preliminary clinical study in children with PSC. METHODS: Published on: Oct-2017 Read more	Lipid profile pattern in pediatric overweight population with or without NAFLD in relation to IDF criteria for metabolic syndrome: a preliminary study https://www.ncbi.nlm.nih.gov/pubmed/29080393 Rom J Intern Med. 2017 Oct 26. pii: /j/rjim.ahead-of-print/rjim-2017-0040/rjim-2017-0040.xml. doi: 10.1515/rjim-2017-0040. [Epub ahead of print] Bălănescu A, Bălănescu P, Comanici V, Stan I, Acs B, Prisăcariu L, Brezan F, Ciomârtan T, Gherghina I. Abstract BACKGROUND AND AIMS: The aim of this study is to assess the lipid profile pattern of pediatric overweight and/or obese patients with Non-Alcoholic Fatty Liver Disease (NAFLD) in relation to IDF Consensus Criteria for Metabolic Syndrome (MetS). MATERIAL AND METHODS: Published on: Oct-2017 Read more
Mucinous Cystadenoma: A Rare Hepatic Tumor in a Child https://www.ncbi.nlm.nih.gov/pubmed/29062832 Front Pediatr. 2017 Oct 9;5:215. doi: 10.3389/fped.2017.00215. eCollection 2017. Ferraguti DA, McGetrick M, Zendejas I, Hernandez-Gonzalo D, Gonzalez-Peralta R. Abstract Published on: Oct-2017 Read more	Long-Term Follow-up after Pediatric Liver Transplantation: Predictors of Growth https://www.ncbi.nlm.nih.gov/pubmed/29077642 J Pediatr Gastroenterol Nutr. 2017 Oct 27. doi: 10.1097/MPG.0000000000001815. [Epub ahead of print] Long-Term Follow-up after Pediatric Liver Transplantation: Predictors of Growth. Loeb N, Owens JS, Strom M, Farassati F, Van Roestel K, Chambers K, Kean P, Ng VL, Avitzur Y, Carricato M, Wales P, Martin GC. Abstract OBJECTIVES: To describe long-term growth post-pediatric liver transplantation and to conduct bivariate and multivariate analysis of factors that may predict post-transplantation growth in children who received a liver transplant from January 1999 to December 2008 at the Hospital for Sick Children. METHODS: Published on: Oct-2017 Read more

CLF Intro movie

SMS requests to

9224791366

Ask The Expert

Pediatric Liver Specialists in India

Centres offering Genetic Testing for Pediatric Liver Diseases

Financial Aid Offered by Trusts

Follow us on:

Facebook Twitter YouTube